Revenue segments as reported by the company.

Smokeable Products

Oral Tobacco Products

Wine

All Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, administration and research costs

Asset impairment and exit costs

Amortization of intangibles

General corporate expenses

Corporate asset impairment and exit costs

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Altria

Altria Group, Inc. operates as a holding company, which engages in the manufacture and sale of cigarettes in the United States. It operates through the following segments: Smokeable Products, Oral tobacco products, and Wine. The Smokeable Products segment consists of cigarettes manufactured and sold by PM USA and machine-made large cigars and pipe tobacco manufactured and sold by Middleton. The Oral tobacco products segment is primarily moist smokeless tobacco products (MSTs) through brands like Copenhagen and Skoal as well as on! oral nicotine pouches sold by Helix. The Wine segment, through subsidiary Ste. Michelle Wine Estates Ltd, produces Washington State wines, primarily Chateau Ste. Michelle and 14 Hands, and owns wineries in or distributes wines from several other wine regions. The company was founded in 1919 and is headquartered in Richmond, VA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Altria reports robust Q4 earnings, focuses on innovation and growth

Altria's Q4 2022 performance reflects resilience amidst industry challenges, with a focus on innovation and shareholder returns. The company's strategic initiatives in smoke-free products and digital engagement underscore its commitment to long-term growth and harm reduction.

Altria reports resilient Q1 performance amid industry challenges and opportunities

Altria's Q1 2023 earnings call highlighted strong performance amidst industry challenges, emphasizing harm reduction and regulatory compliance. The company faces hurdles from inflation, regulatory changes, and evolving consumer behaviors, while focusing on growth opportunities in smoke-free products and strategic investments.

Altria reports solid Q2 earnings, eyes e-vapor growth opportunities

Altria's focus on smoke-free products and NJOY acquisition driving growth.
Challenges in the cigarette industry due to economic pressures and flavor bans.
Opportunities in the e-vapor category and expansion plans in the U.S.
Strong balance sheet and significant capital returns to shareholders.

Altria reports growth in earnings, navigates regulatory challenges in e-vapor

Altria's Q3 2023 earnings call highlighted solid financial performance, strategic focus on e-vapor products, and efforts to combat illegal vape products. The company faces challenges from regulatory uncertainties and illicit products but sees opportunities in expanding NJOY's reach and addressing market gaps.

Altria reports growth in smoke-free products amidst regulatory challenges

Altria's Q4 2023 earnings call highlighted growth in adjusted EPS, strategic focus on smoke-free products, and efforts to combat illicit e-vapor products. The company faces challenges in competitive segments and economic pressures but sees opportunities in new product introductions and regulatory collaborations.

Altria reports mixed Q1 performance, focuses on growth strategies

Altria's Q1 performance showed growth in NJOY and oral tobacco segments, with challenges in EPS decline and economic pressures on consumers.
Strengths include reaffirmed EPS guidance, strategic investments, and focus on combating illicit e-vapor products.
Opportunities lie in maximizing profitability in oral tobacco, product positioning, and capturing transitioning consumers.
Overall, Altria's performance reflects a mix of growth, challenges, and strategic opportunities in navigating market dynamics.

Altria's NJOY drives growth as company navigates e-vapor challenges

Altria's Q2 2024 earnings call showcased strong performance in smoke-free products, highlighting growth in retail share and volume momentum. Despite challenges in the e-vapor category, the company remains focused on responsible regulation and enforcement. With a commitment to shareholder value and long-term growth strategies, Altria is poised for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Altria Group, Inc. is a holding company, which engages in the manufacture and sale of cigarettes in the United States. It operates through the following segments: Smokeable Products, Oral Tobacco Products, and All Other. The Smokeable Products segment consists of cigarettes manufactured and sold by PM USA, and machine-made large cigars and pipe tobacco manufactured and sold by Middleton. The Oral Tobacco Products segment includes MST and snus products manufactured and sold by USSTC, and oral nicotine pouches manufactured and sold by Helix. The All Other segment refers to the financial results of NJOY, Helix ROW, and the IQOS System heated tobacco business. The company was founded in 1919 and is headquartered in Richmond, VA.

AbbVie

Abbott Labs

Black Hills

Emerson Electric

Federal Realty Investment Trust

Johnson & Johnson

Coca-Cola

Leggett & Platt

Lowe's

National Fuel Gas

Northwest Natural Gas

Sysco

Universal Corp

V.F.

"There is only one-criterion to be included among the Dividend Kings: a publicly-traded company must increase its total fiscal-year dividend-payout for a minimum of 50 consecutive years."--Dogs of the Dow. The 47 Dividend Kings screened as of February 24, 2023, represented eight of eleven Morningstar Sectors. Broker targeted-top-ten net-gainers ranged 15.54%-31.75% topped-by NFG & VFC.

March Dividend Kings: 5 Buys, 4 To Watch

Altria is reportedly in "advanced talks" to acquire #3 U.S. e-cigarette maker NJOY for $2.75bn. We see this as the wrong decision. NJOY is a distant #3 in U.S. Vapor. Precedents elsewhere suggest it is unlikely to catch up, absent drastic regulatory intervention.

Altria: Buying NJOY Would Likely Bring No Joy

A mooted $2.75 billion deal for e-cigarette brand NJOY is smaller than the tobacco giant's ill-fated 2018 investment in Juul, but the valuation is punchier.

Altria's Latest Vape Could Be Even Pricier Than Its First

Altria Group Inc, one of the world's largest producers and marketers of tobacco, cigarettes, and related products, is reportedly in advanced talks to buy e-cigarette startup NJOY Holdings Inc for at least $2.75 billion. According to a report by The Wall Street Journal citing people familiar with the matter, the deal for NJOY, one of the few e-cigarette makers to have secured clearance from federal regulators, could be announced as soon as this week.

Altria reportedly in talks to buy vaping startup NJOY for at least $2.75B

The Marlboro maker is looking to take over a new vaping brand after its bet on Juul fizzled.

Altria in Talks to Buy Vaping Startup NJOY

During tough times, this stock has been a potential market-beater in terms of total return.

Why This Cheap High-Yield Stock Is a Top Recession Pick

British American Tobacco

Enbridge

Enterprise Products Partners

KFA Mount Lucas Index Strategy ETF

Legal & General Group PLC

Magellan Midstream Partners

MPLX

ONEOK

Schwab US Dividend Equity ETF

Verizon

2023 is a time of maximum economic, inflation, and interest rate uncertainty. Stocks are likely to finish flat for the year, but might fall up to 20% along the way. High-yield investors are perfectly positioned to profit from the coming bull market because they are collecting safe 5% to 9% dividends while waiting for the bear market to end.

Build A 7%-Yielding Dream Retirement Portfolio With 12 Amazing Blue Chips

Refusing simple math can be detrimental to our returns. I am a proponent of long-term investing but that does not mean eternity.

Altria Group: The 8-Year Plan

Colgate-Palmolive

Costco

Estee Lauder

General Mills

Kroger

PepsiCo

Procter & Gamble

Philip Morris

Target

Tyson Foods

Unilever

Walmart

But what are consumer staples stocks, and why should you consider adding them to your investment portfolio? We will teach you how and why consumer staples stocks are essential.

What Are Consumer Staples Stocks?

Bank of America

BASF SE

Citigroup

Chevron

Healthpeak Properties Inc

Healthcare Realty Trust Inc

HSBC Holdings

Imperial Brands PLC

JPMorgan Chase & Co

Kimco Realty

Medical Properties Trust

Muenchener Rueckversicherungs-Gesellschaft AG in Muenchen

National Retail Properties

Realty Income Corp

Omega Healthcare Investors

Occidental Petroleum

Regency Centers

Reinsurance Group of America

In this article, I will present 10 companies that could help you generate an additional income. All the picks that I present in this article provide you with an attractive Dividend Yield.

10 High-Yield Dividend Stocks To Help You Generate Income

Energy Transfer LP Unit

Prudential Financial

Many large-caps reward their shareholders with dividends, providing a beneficial advantage. And let's face it, payday is always the best.

3 Large-Cap Stocks With Big Dividend Yields

Walgreens

Are these dividend stocks on your watchlist today?

Best Stocks To Buy Now? 2 Top Dividend Stocks In Focus

EPR Properties

OneMain Hld

Pioneer Natural Resources

The stock market has been giving investors whiplash recently. So it is no surprise many folks are looking for stability and big dividends.

Top Analysts Pound the Table Now on 5 ‘Strong Buy' Stocks Yielding 7% or More

Japan Tobacco Inc

Altria and Japan Tobacco have identical annual revenue. Altria and Japan Tobacco have entered into an agreement to sell JAPAY's HTS (Heated Tobacco Stick) Ploom X in the US.

Altria Vs. Japan Tobacco: Which Company Is The Best Investment For 2023?

Many Consumer Staples stocks pay dividends, providing a passive income stream and a cushion against the impacts of drawdowns. And these three stocks are no different, all currently yielding more than 2.5% annually.

Like Income? 3 Consumer Staples Stocks Worth a Look

Allianz SE

AXA SA

BHP Billiton

Corteva Inc

In this article, I will show you how you could build an investment portfolio that aims to reach a relatively high Dividend Yield. I will demonstrate how you could allocate $50,000 among 10 high yield dividend income companies and ETFs while achieving a broad risk diversification.

How To Allocate $50,000 Among 10 High Yield Dividend Income Stocks And ETFs

News for Altria Stock (MO)